Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection
- PMID: 29024739
- DOI: 10.1016/j.pharmthera.2017.10.009
Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection
Abstract
Hepatitis C virus (HCV) is a global health problem, because infection frequently leads to chronic hepatitis C eventually progressing to liver cirrhosis and liver cancer. Improved insights into the HCV replication cycle and the role of HCV non-structural proteins have recently enabled to identify drugs directly acting on specific HCV target structures. Agents from three drug classes have been developed and approved by the health authorities. Combinations of two or more drugs from different classes achieve high (>90%) HCV clearance rates and are well tolerated. This interferon-free DAA (direct antiviral agent) therapy has revolutionized antiviral therapy in hepatitis C so that successful hepatitis C treatment can be offered to virtually all patients irrespective of their co-morbidity. This review provides an overview over currently approved regimens and outlines their use in clinical practice. In addition potential short-comings of the current therapeutic options such as drug-drug interactions and selection of viral resistance are addressed. DAA combination therapy has the potential to obtain global control over hepatitis C. However, easy access to DAAs, availability of reliable HCV diagnostics, and affordable costs remain still important goals, which must be reached to globally eliminate hepatitis C.
Keywords: HCV NS5A inhibitor; HCV polymerase inhibitor; HCV proteinase inhibitor; HCV therapy; HCV viral resistance; Hepatitis C.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.Antiviral Res. 2017 Oct;146:149-152. doi: 10.1016/j.antiviral.2017.09.001. Epub 2017 Sep 4. Antiviral Res. 2017. PMID: 28882564 Free PMC article.
-
Antiviral resistance and direct-acting antiviral agents for HCV.Antivir Ther. 2012;17(6 Pt B):1147-62. doi: 10.3851/IMP2426. Epub 2012 Oct 5. Antivir Ther. 2012. PMID: 23188771 Review.
-
[Progress in Examination and Treatment of Hepatitis C Virus].Rinsho Byori. 2015 Jun;63(6):762-7. Rinsho Byori. 2015. PMID: 26548242 Review. Japanese.
-
Direct-acting antivirals: the endgame for hepatitis C?Curr Opin Virol. 2017 Jun;24:31-37. doi: 10.1016/j.coviro.2017.03.017. Epub 2017 Apr 15. Curr Opin Virol. 2017. PMID: 28419938 Review.
-
Hepatitis C virus resistance to protease inhibitors.J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. J Hepatol. 2011. PMID: 21284949 Review.
Cited by
-
Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition.Sci Rep. 2021 May 6;11(1):9719. doi: 10.1038/s41598-021-89271-8. Sci Rep. 2021. PMID: 33958691 Free PMC article.
-
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level.Health Sci Rep. 2021 May 2;4(2):e273. doi: 10.1002/hsr2.273. eCollection 2021 Jun. Health Sci Rep. 2021. PMID: 33969232 Free PMC article.
-
NOX as a Therapeutic Target in Liver Disease.Antioxidants (Basel). 2022 Oct 16;11(10):2038. doi: 10.3390/antiox11102038. Antioxidants (Basel). 2022. PMID: 36290761 Free PMC article. Review.
-
Risk factors for loss to follow-up after the start of direct-acting antiviral treatment for hepatitis C virus infection.JGH Open. 2022 Dec 30;7(2):98-104. doi: 10.1002/jgh3.12855. eCollection 2023 Feb. JGH Open. 2022. PMID: 36852151 Free PMC article.
-
Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals.J Pers Med. 2023 Jul 26;13(8):1188. doi: 10.3390/jpm13081188. J Pers Med. 2023. PMID: 37623439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
